Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase.
Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk. 2013 Dec 9; Authors: Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE Abstract BACKGROUND: Accelerated phase CML most frequently represents a progression state in CML. However, some patients present with AP features at the time of diagnosis. There is limited information on the outcome of these patients who received TKIs as initial therapy. PATIENTS AND METHODS: We analyzed the outcome of 51 consecutive patients with CML who presented with features of AP at the time of diagnosis, including blasts ≥ 15% (n = 6), basophils ≥ 20% (n = 22), platelets
Publication date: Available online 18 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hayri Bostan, Tayfur Toptas, Funda Pepedil Tanrikulu, Kevser Kut, Fatma Arikan, Fergun Yilmaz, Isik Atagunduz, Tulin Firatli-Tuglular
Abstract The diagnostic approach to thrombocytosis involves consideration of reactive, hereditary, and neoplastic causes. Once reactive causes of thrombocytosis, such as iron deficiency, infections, solid tumors, and other obvious causes such as post-splenectomy thrombocytosis, have been ruled out, the focus shifts to myeloid malignancies, such as chronic myeloid leukemia (CML), the classic Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), primary myelofibrosis (PMF), polycythemia vera (PV), myelodysplastic syndrome (MDS) with isolated deletion 5q and the r...
Abstract Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis, clinically heterogeneous entity termed 'BCR-ABL1 negative CML' constituting about 5% of CML cases. Apart from very rare CML cases with cytogenetically cryptic, atypical variant BCR-ABL1 fusions that had been inadvertently missed during the diagnostic work up, most of these cases would now be classified as a subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN), such as atypical CML (aCML), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemi...
CONCLUSIONS: There was no convincing evidence of an increased risk in any hematological malignancy when interpreting the results from both series of analyses. PMID: 32818321 [PubMed - as supplied by publisher]
Publication date: Available online 18 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hayri Bostan, Tayfur Toptas, Funda Pepedil Tanrikulu, Kevser Kut, Fatma Gecgel, Fergun Yilmaz, Isik Atagunduz, Tulin Firatli-Tuglular
We assessed the quality of life and symptom burden in patients with chronic-phase chronic myeloid leukemia (CML) receiving first- or second-generation tyrosine kinase inhibitors, to demonstrate whether there are differences between tyrosine kinase inhibitor generations. A total of 121 patients with CML with good performance and low comorbidity scores were enrolled in the study. Similar results were observed between the groups in the quality of life and symptom burden scores, which were examined using CML-specific (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chronic Myeloid Leuke...
Publication date: Available online 16 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Publication date: June 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 6Author(s): Olga V. Lazareva, Anna G. Turkina, Ekatarina Yu. Chelysheva, Anton A. Kulikovsky, Maria V. Galayko, Olga M. Senderova, Valentina M. Pepeliaeva, Sergey V. Meresiy, Alexandr S. Luchinin, Galina I. Milutina, Lyubov V. Gavrilova, Lyudmila B. Avdeeva, Elena B. Dasheeva, Olga Yu. Vinogradova, Hunan L. Julhakyan, Sergey M. Kulikov
Publication date: May 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 5Author(s): Shashidhar V. Karpurmath, Arun Seshachalam, Kalaiselvi Selvaraj, Priyadarshini Rajamani, Satish kumar, Neelesh Reddy, Baswant Malipatil, Roopa Sirigeri, Krishna Prasad, Krishna Reddy, Madhav Danthala, Karthik S. Udupa, Manjunath Nandennavar, Janarthinakani Murugesan, C.N. Patil, Parameswaran Anoop, Roshan Koshy Jacob, Mallikarjun Kalashetty, Krishnakumar Rathnam, Ramanan Ganapathy
Publication date: May 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 5Author(s): Anna Petrova, Ekaterina Chelysheva, Oleg Shukhov, Anastasiya Bykova, Irina Nemchenko, Galina Gusarova, Nikolay Tsyba, Hunan Julhakyan, Vasiliy Shuvaev, Mikhail Fominykh, Irina Martynkevich, Tatyana Ionova, Anna Turkina